
    
      This was a prospective, randomized, multicenter, blinded, parallel-group, active-controlled,
      non-inferiority study conducted at 13 sites within the US. Eligible patients participated in
      8 treatment visits on Days 1, 2, 3, 4, 8, 15, 22, and 29. Effectiveness of treatment was
      assessed as follows:

        -  Retention in treatment at Day 3

        -  Clinician and patient assessments of opioid withdrawal symptoms

        -  Assessment opioid cravings
    
  